Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
127,940,509
-
Total 13F shares
-
80,524,601
-
Share change
-
+1,674,104
-
Total reported value
-
$540,295,292
-
Put/Call ratio
-
236%
-
Price per share
-
$6.71
-
Number of holders
-
119
-
Value change
-
+$11,110,651
-
Number of buys
-
64
-
Number of sells
-
38
Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q1 2024
As of 31 Mar 2024,
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) was held by
119 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
80,524,601 shares.
The largest 10 holders included
BlackRock Inc., BROWN CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, RA CAPITAL MANAGEMENT, L.P., HHLR ADVISORS, LTD., STATE STREET CORP, NEW YORK STATE COMMON RETIREMENT FUND, GEODE CAPITAL MANAGEMENT, LLC, DIMENSIONAL FUND ADVISORS LP, and WELLINGTON MANAGEMENT GROUP LLP.
This page lists
119
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.